PP
VKTX icon

PDT Partners’s Viking Therapeutics VKTX Stock Holding History

PDT Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-46,758
Closed -$127K – 905
2022
Q3 		$127K Sell
46,758
-35,481
-43% -$116K 0.02% 769
2022
Q2 		$238K Hold
82,239
– – 0.02% 793
2022
Q1 		$247K Sell
82,239
-54,076
-40% -$194K 0.02% 774
2021
Q4 		$627K Buy
136,315
+32,372
+31% +$181K 0.05% 476
2021
Q3 		$653K Sell
103,943
-33,300
-24% -$206K 0.05% 416
2021
Q2 		$822K Buy
137,243
+94,948
+224% +$564K 0.05% 408
2021
Q1 		$268K Buy
+42,295
New +$298K 0.02% 647
2020
Q4 		– Sell
-48,294
Closed -$281K – 863
2020
Q3 		$281K Buy
+48,294
New +$333K 0.02% 559
2020
Q1 		– Sell
-32,329
Closed -$259K – 870
2019
Q4 		$259K Buy
+32,329
New +$236K 0.02% 581

Other funds holding VKTX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PDT Partners's VKTX Position: Q4 2022 in Review

PDT Partners sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 46,758 shares — an estimated $127K sold.

PDT Partners first reported a position in VKTX in Q4 2019 and held it in 9 quarters. The position peaked at $822K in Q2 2021. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • PDT Partners reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 46,758 Viking Therapeutics shares in Q4 2022, an estimated $127K.
  • PDT Partners first reported a position in Viking Therapeutics in Q4 2019 and held it in 9 quarters.
  • PDT Partners's Viking Therapeutics position peaked at $822K in Q2 2021.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.